Malaria

Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- On October 29, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its operating performance for the first three quarters of 2024. From January to September 2024, Fosun Pharma achieved revenue of RMB30.91 billion, an increase of about 5.74% YoY after excluding COVID-related products. The net profit attributable to owners of the parent of the Group after deducting extraordinary gain or loss amounted to RMB1.84 billion, up by 24.58% YoY. In 2024, Fosun Pharma will further focus on innovative drugs and high-value devices, and continue to promote lean operations, cost reduction, efficiency improvement, and asset rationalization to optimize assets and financial structure, actively promote supply chain management and operational efficiency, and achieve healthy operating cash flow. In the first three quarters of 2024, the net cash flow from operating activities of Fosun Pharma was RMB2.99 billion, a year-on-year increase of 21.33%; the management expense ratio decreased by 0.15 percentage points YoY; excluding the impact of newly acquired companies, management expenses decreased by approximately RMB300 million on the same basis. Focusing on advantageous therapeutic areas with innovative R&D pipelines continue to advance In terms of innovative R&D, Fosun Pharma continues to focus on advantageous pipelines to achieve efficient results and continuous implementation of innovative products. In the first three quarters of 2024, Fosun Pharma's R&D expenditure totaled RMB3.92 billion. In particular, R&D expenses were RMB2.65 billion. In addition to independent R&D, the Group fully implemented an open R&D model, and incubated and invested in R&D projects by initiating/managing industrial funds and other diversified ways, so as to ensure the sustainability of innovation and R&D. Fosun Pharma's innovative drug business mainly covers the core therapeutic areas of solid tumors, hematological tumors and immuno-inflammatory diseases, with emphasis on the enhancement of the core technology platforms of antibody/ADCs, cellular therapy and small molecules, to create an open and global innovative R&D system, continuously enhance pipeline value, and promote the development and commercialization of its products. In the field of tumor immunotherapy, on September 13, 2024, Fosun Pharma announced it will acquire the 50% stake in Fosun Kite and will wholly own Fosun Kite (now renamed as "Fosun Kairos"). In the future, Fosun Kairos will serve as the core platform of Fosun Pharma's cell therapy, continue to focus on the field of tumor immunotherapy, as well as to promote the development and commercialization of existing licensed products, Axi-Cel (i.e. Fosun Kite's marketed product "Yi Kai Da") and Brexu-Cel (i.e. Fosun Kite's pipeline project FKC889), in Chinese mainland, Hong Kong SAR and Macau SAR with Kite Pharma. In the third quarter of 2024, Fosun Pharma's multiple independently developed innovative products and pipeline clinical trial results were announced in industry conferences and journals, further consolidating its dominant position in the fields of hematological tumors, breast cancer, lung cancer and other tumors. Particularly, the interim analysis results of the Phase III study of Foritinib Succinate (SAF-189s), an innovative drug independently developed to treat ALK-positiveb advanced non-small cell lung cancer (NSCLC), were released during the 2024 World Conference on Lung Cancer ("WCLC"). The above-mentioned studies have found that the overall efficacy of Foritinib Succinate is good. Compared with crizotinib treatment, it can significantly improve PFS and reduce the risk of CNS progression. Its safety is controllable, and no new safety signals appeared after treatment. Faritinib Succinate is expected to break through the current clinical difficulties faced in the treatment of ALK-positive NSCLC and bring new treatment options to NSCLC patients. The multicenter real-world study of Fosun Pharma's self-developed serplulimab-based immunochemotherapy for extensive-stage small cell lung cancer was released at the 2024 WCLC. The ASTRUM-005R study provides additional empirical evidence to support the therapeutic value of serplulimab plus chemotherapy and complements the pivotal data from the ASTRUM-005 clinical trial. Additionally, during the reporting period, the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency (EMA) issued a positive opinion recommending approval for Fosun Pharma's self-developed serplulimab injection in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). The CHMP's opinion will be submitted to the European Commission (EC) as a reference for marketing authorization approval. Results of the phase 2 study of HLX22, an innovative anti-HER2 monoclonal antibody (mAb), in combination with Han Qu You (trastuzumab) and chemotherapy for the first-line treatment of HER2-positive advanced gastric/gastroesophageal junction (G/GEJ) cancer were presented on 2024 ESMO Gastrointestinal Cancers Congress (ESMO GI) and MED, a flagship clinical and translational research monthly journal by Cell Press. The results showed that add HLX22 to HLX02 (trastuzumab) and chemotherapy as first-line therapy improved efficacy in HER2-positive G/GEJ cancer patients with manageable safety. In September 2024, Fosun Pharma announced the Biologics License Application ("BLA") for the licensed product RT002 (DaxibotulinumtoxinA-lanm, Chinese trademark: 达希斐®) for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients, was approved by the National Medical Products Administration ("NMPA"), becoming the first DaxibotulinumtoxinA-lanm approved for marketing in Chinese mainland. Additionally, the results of a Phase III multicenter, double-blind, placebo-controlled study conducted in China for the treatment of moderate to severe glabellar lines were published in the Journal of Plastic, Reconstructive & Aesthetic Surgery (JPRAS). The study demonstrates that the product provides durable efficacy and high safety in Chinese patients with moderate to severe glabellar lines. Actively implementing share repurchases and increasing holdings with continuous efforts on enhancing ESG Fosun Pharma, a company listed on both the A-share and H-share markets, and its controlling shareholder Fosun High Tech have actively engaged in share repurchases and increased holdings this year, demonstrating confidence in the Company's future development and further boosting market confidence. In the first three quarters of 2024, Fosun Pharma spent approximately RMB127 million and approximately HKD66.9 million to repurchase around 5.68 million A shares and 5.47 million H shares respectively. As of now, the H Share Repurchase Plan is still valid. In addition, the controlling shareholder Fosun High Tech, has spent a total of approximately RMB101 million to increase its holdings of around 4.30 million A shares of Fosun Pharma, under the latest Shareholding Increase Plan. Founded in 1994 and with three decades of development, Fosun Pharma has grown into a global innovation-driven pharmaceutical and healthcare industry group. The Company always regards innovation as its primary social responsibility, consistently focusing on unmet clinical needs, prioritizing innovative R&D, advancing the launch of innovative products, promoting drug accessibility and affordability, and driving high-quality corporate growth. Fosun Pharma maintained an A grade rating in MSCI ESG Ratings for three consecutive years and an A- rating in HSI ESG, ranking among the top tier in the healthcare industry for pharmaceuticals and biotechnology. It was also selected as a constituent of the Hang Seng (China A) Corporate Sustainability Benchmark Index ("HSCASUSB"), Hang Seng (China A) Corporate Sustainability Index ("HSCASUS"), and Hang Seng (Mainland and HK) Corporate Sustainability Index ("HSMHSUS"). With its sustained excellence in innovation and global operational capabilities, Fosun Pharma has been recognized by multiple authoritative institutions in innovative R&D, ESG and other areas. The Company ranked in the top four of China's 2023 Top 100 Pharmaceutical Industry, was included in the "China Best Managed Companies" List (BMC) for the second consecutive year and was listed in Forbes 2024 China ESG 50. In addition, the Company has actively introduced its independently developed artemisinin-based innovative products to Africa, providing a Chinese solution to the global fight against malaria. This initiative highlights the inclusive, diverse, and open nature of ESG and earned Fosun Pharma recognition as an "Inspirational ESG Case", serving as a model for corporate ESG practices. *** About Fosun Pharma Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma's innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules. Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of "Innovation for Good Health", continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation. For more information, please visit the official website: SOURCE Fosun Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

BERKELEY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- HOPO Therapeutics, Inc. announced today that it has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. The funds will be used to advance development of the drug candidate HOPO-101 through registrational studies as a medical countermeasure against radiological threats, including planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The initial award of approximately $9.4 million will fund toxicology and pharmacology studies, manufacturing activities, and nonclinical research in other types of heavy metal poisoning, with approximately $216 million in additional funding available for later-stage development upon agreement between BARDA and HOPO. The ongoing Phase 1 clinical study of HOPO-101 (NCT05628961), as well as earlier nonclinical work, has been funded by the National Institute of Allergy and Infectious Diseases. There are no approved oral therapies to treat individuals exposed to radioactive heavy metals like plutonium, americium, and curium. In the event of a radiological or nuclear disaster, treatment with a decorporation agent – a drug designed to bind and accelerate the clearance of heavy metals from the body – is the only practical means to mitigate the risk of radiation poisoning. HOPO Therapeutics is developing decorporation agents that can be taken orally, with the aim of providing rapid access to treatment for an exposed population. This BARDA funding will also be used to study HOPO-101 as a possible treatment for lead poisoning. As recently highlighted by several leading global health organizations including the U.S. Agency for International Development (USAID), lead poisoning kills an estimated 1.5 million people each year, more than malaria and HIV combined. Most of these deaths, and the over 800 million children currently suffering from lead poisoning, are in low- and middle-income communities. “We are thrilled to partner with BARDA on the development of a new oral decorporation agent for radiological threat preparedness,” said Dr. Julian Rees, HOPO’s Chief Executive Officer and co-founder. “We believe that HOPO-101 can fill an important gap in the world’s ability to respond to a nuclear or radiological disaster, a scenario made ever more likely by ongoing conflicts around the world, and that it could also help to address one of the most significant unmet needs in global health. Nonclinical studies indicate that HOPO-101 would be a substantial improvement over the existing standard of care, and we are delighted to have BARDA’s support in exploring its dual-use capability as both a medical countermeasure and a potential treatment for lead poisoning in adults and children.” Funding for this award was received under contract through BARDA’s Broad Agency Announcement. This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50124C00062. About HOPO Therapeutics HOPO Therapeutics is a privately-held, clinical-stage pharmaceutical company developing treatments for heavy metal poisoning and pioneering novel methods for directed radioisotope delivery. Leveraging world-class expertise in the chemistry and biochemistry of heavy metals and technology licensed from Lawrence Berkeley National Laboratory, HOPO’s mission is to safeguard all people throughout the world from the harmful effects of heavy metal contamination while utilizing the power of metals in medicine to cure disease and improve lives. For more information, please visit www.hopotx.com.

Celebrating its golden anniversary, Nikon Small World honors a stunning photo of brain tumor cell structures, advancing our understanding of neurodegenerative diseases. MELVILLE, N.Y., Oct. 17, 2024 /PRNewswire/ -- Nikon Instruments Inc. today announced the winners of the 50th annual Nikon Small World Photomicrography Competition, celebrating five decades of excellence in microscopy and digital imaging. This year's first place prize was awarded to Dr. Bruno Cisterna, with assistance from Dr. Eric Vitriol of Augusta University, for his groundbreaking image of differentiated mouse brain tumor cells, highlighting the actin cytoskeleton, microtubules, and nuclei. This image reveals how disruptions in the cell's cytoskeleton – the structural framework and "highways" known as microtubules – can lead to diseases like Alzheimer's and ALS. Continue Reading Differentiated mouse brain tumor cells (actin, microtubules, and nuclei) Dr. Cisterna's research revealed that profilin 1 (PFN1), a protein crucial for building the cell's structure, plays a key role in maintaining the microtubule highways essential for cellular transport. When PFN1 or related processes are disrupted, these highways can malfunction, leading to cellular damage similar to what is observed in neurodegenerative diseases. "One of the main problems with neurodegenerative diseases is that we don't fully understand what causes them," said Dr. Cisterna. "To develop effective treatments, we need to figure out the basics first. Our research is crucial for uncovering this knowledge and ultimately finding a cure. Differentiated cells could be used to study how mutations or toxic proteins that cause Alzheimer's or ALS alter neuronal morphology, as well as to screen potential drugs or gene therapies aimed at protecting neurons or restoring their function." His patience and determination were crucial in capturing his image. "I spent about three months perfecting the staining process to ensure clear visibility of the cells. After allowing five days for the cells to differentiate, I had to find the right field of view where the differentiated and non-differentiated cells interacted. This took about three hours of precise observation under the microscope to capture the right moment, involving many attempts and countless hours of work to get it just right." The hard work behind this discovery underscores its significance, bringing researchers closer to answers that could potentially transform millions of lives. "After three years of research, we finally published our findings four months ago in the Journal of Cell Biology, and there's still more work to be done," said Dr. Cisterna. "I'm deeply passionate about scientific imaging; I've been following the Nikon Small World contest for about 15 years. It's an incredible contest that highlights the beauty of photomicrography but also inspires continued exploration and innovation in the field." Eric Flem, Senior Manager, CRM and Communications at Nikon Instruments, shares a similar perspective on the competition. "At 50 years, Nikon Small World is more than just an imaging competition – it's become a gallery that pays tribute to the extraordinary individuals who make it possible. They are the driving force behind this event, masterfully blending science and art to reveal the wonders of the microscopic world and what we can learn from it to the public." He went on to add, "Sometimes, we overlook the tiny details of the world around us. Nikon Small World serves as a reminder to pause, appreciate the power and beauty of the little things, and to cultivate a deeper curiosity to explore and question." Second place was awarded to Dr. Marcel Clemens for his image of an electrical arc between a pin and a wire, produced by applying a potential difference of 10,000 volts. Third place was awarded to Chris Romaine for his image of a cannabis plant leaf. The bulbous structures are trichomes, or hair-like plant appendages, and the bubbles inside are cannabinoid vesicles, fluid-filled, blister-like structures. In total, Nikon Small World recognized 87 photos out of thousands of entries from scientists and artists across the globe. The 2024 judging panel included: Adrian Coakley, Director of Photography at National Geographic Books Michelle S. Itano, Ph.D., Assistant Professor of Cell Biology and Physiology and Director of the Neuroscience Microscopy Core at the University of North Carolina at Chapel Hill Emily Petersen, Photography Managing Editor at Science Magazine Clare Waterman, Ph.D., Cell Biologist and Member of the National Academy of Sciences Jennifer C. Waters, Ph.D., Director of the Core for Imaging Technology & Education at Harvard Medical School Samantha Yammine, Ph.D., Neuroscientist and Science Communicator For additional information, please visit , or follow the conversation on Facebook, Twitter @NikonSmallWorld and Instagram @NikonInstruments. NIKON SMALL WORLD WINNERS 1st Place Dr. Bruno Cisterna & Dr. Eric Vitriol Medical College of Georgia at Augusta University Department of Neuroscience & Regenerative Medicine Augusta, Georgia, USA Differentiated mouse brain tumor cells (actin, microtubules, and nuclei) Super-Resolution 100X (Objective Lens Magnification) 2nd Place Dr. Marcel Clemens Verona, Veneto, Italy Electrical arc between a pin and a wire Image stacking for the pin and wire combined with long exposure for the electrical arcs 10X (Objective Lens Magnification) 3rd Place Chris Romaine Kandid Kush Port Townsend, Washington, USA Leaf of a cannabis plant. The bulbous glands are trichomes. The bubbles inside are cannabinoid vesicles. Image Stacking 20X (Objective Lens Magnification) 4th Place Dr. Amy Engevik Medical University of South Carolina Department of Regenerative Medicine & Cell Biology Charleston, South Carolina, USA Section of a small intestine of a mouse Fluorescence 10X (Objective Lens Magnification) 5th Place Thomas Barlow & Connor Gibbons Columbia University Department of Neurobiology and Behavior New York, New York, USA Cluster of octopus (Octopus hummelincki) eggs Darkfield, Stereomicroscopy, Focus Stacking 3X (Objective Lens Magnification) 6th Place Henri Koskinen Helsinki University Helsinki, Uudenmaan lääni, Finland Slime mold (Cribraria cancellata) Image Stacking, Polarized Light, Reflected Light 10X (Objective Lens Magnification) 7th Place Gerhard Vlcek Maria Enzersdorf, Austria Cross section of European beach grass (Ammophila arenaria) leaf Brightfield, Image Stacking 10X (Objective Lens Magnification) 8th Place Stephanie Huang Victoria University of Wellington School of Biological Sciences; School of Psychology Wellington, New Zealand A neuron densely covered in dendritic spines from the striatum of an adult rat brain Confocal, Deconvolution, Image Stacking 60X (Objective Lens Magnification) 9th Place John-Oliver Dum Medienbunker Produktion Bendorf, Rheinland Pfalz, Germany Pollen in a garden spider (Araneus) web Image Stacking 20X (Objective Lens Magnification) 10th Place Jan Martinek Charles University Department of Experimental Plant Biology Prague, Czech Republic Spores of black truffle (Tuber melanosporum) Confocal 63X (Objective Lens Magnification) 11th Place Dr. Ferenc Halmos Bánd, Veszprém, Hungary Slime mold on a rotten twig with water droplets Image Stacking 0.7X - 4.5X (Objective Lens Magnification) 12th Place Daniel Knop Oberzent-Airlenbach, Hessen, Germany Wing scales of a butterfly (Papilio ulysses) on a medical syringe needle Image Stacking 20X (Objective Lens Magnification) 13th Place Paweł Błachowicz Bedlno, Świętokrzyskie, Poland Eyes of green crab spider (Diaea dorsata) Image Stacking, Reflected Light 20X (Objective Lens Magnification) 14th Place Marek Miś Marek Miś Photography Suwalki, Podlaskie, Poland Recrystallized mixture of hydroquinone and myoinositol Polarized Light 10X (Objective Lens Magnification) 15th Place Sébastien Malo Saint Lys, Haute-Garonne, France Isolated scales on Madagascan sunset moth wing (Chrysiridia ripheus) Darkfield, Image Stacking, Reflected Light 40X (Objective Lens Magnification) 16th Place Marek Miś Marek Miś Photography Suwalki, Podlaskie, Poland Two water fleas (Daphnia sp.) with embryos (left) and eggs (right) Darkfield, Polarized Light 10X (Objective Lens Magnification) 17th Place Dr. Frantisek Bednar Svosov, Zilinsky, Slovak Republic Stonewort algae (Chara virgata) reproductive organs - oogonia (female organs) and antheridia (male organs) Darkfield 4X (Objective Lens Magnification) 18th Place Alison Pollack San Anselmo, California, USA An insect egg parasitized by a wasp Image Stacking, Reflected Light 10X (Objective Lens Magnification) 19th Place Alison Pollack San Anselmo, California, USA Seed of a Silene plant Image Stacking, Reflected Light 10X (Objective Lens Magnification) 20th Place Dr. Bruno Cisterna & Dr. Eric Vitriol Medical College of Georgia at Augusta University Department of Neuroscience & Regenerative Medicine Augusta, Georgia, USA Early stage of mouse neuroblastoma cell differentiation (actin, microtubules, and mitochondria) Super-Resolution 100X (Objective Lens Magnification) HM Christopher Algar Hounslow, Middlesex, United Kingdom Brine shrimp Darkfield, Image Stacking, Polarized Light 4X (Objective Lens Magnification) HM Dr. Kseniia Bondarenko University of Edinburgh Institute for Immunology and Infection Research Edinburgh, MidLothian, United Kingdom Acute-stage parasites of Toxoplasma gondii in a human skin cell Expansion Microscopy, Confocal, Deconvolution 100X (Objective Lens Magnification) HM Dr. Anja de Lange University of Cape Town Neuroscience Institute & Department of Human Biology Cape Town, Western Cape, South Africa Astrocytes surrounding a blood vessel in a thin slice of human brain Confocal 40X (Objective Lens Magnification) HM Dr. Amy Engevik Medical University of South Carolina Department of Regenerative Medicine & Cell Biology Charleston, South Carolina, USA Intestinal villi Fluorescence 20X (Objective Lens Magnification) HM Daniel Evrard Aywaille, Liege, Belgium Vinyl player needle on scratched vinyl disk Image Stacking, Polarized Light 20X (Objective Lens Magnification) HM Randy Fullbright Fullbright Studio Vernal, Utah, USA Agatized dinosaur bone Image Stacking 10X (Objective Lens Magnification) HM Dr. David Maitland St. Andrews, Fife, United Kingdom Transverse section of rachis (stem) of bracken fern (Pteridium aquilinum) Differential Interference Contrast (DIC) 5X (Objective Lens Magnification) HM Angus Rae Australian National University Centre for Advanced Microscopy MacGregor, Australian Capital Territory, Australia Autofluorescence in the face of a little two-spotted ladybird (Diomus notescens) Fluorescence lifetime imaging microscopy (FLIM) 20X (Objective Lens Magnification) HM Dr. Igor Robert Siwanowicz Howard Hughes Medical Institute (HHMI), Janelia Research Campus Ashburn, Virginia, USA Antenna of a mole crab Confocal 10X (Objective Lens Magnification) HM Jochen Stern Mannheim, Baden-Wuerttemberg, Germany Golden bug eggs on a sage leaf Image Stacking 20X (Objective Lens Magnification) HM Dr. Bruce Douglas Taubert Glendale, Arizona, USA Ocelli between the compound eyes of a yellow jacket Reflected Light 10X (Objective Lens Magnification) HM Kevin Terretaz CRBM-CNRS Montpellier, Hérault, France Mosquito cells in culture with fluorescent markers for DNA and microtubules Confocal 63X (Objective Lens Magnification) IoD Dr. Sherif Abdallah Ahmed Tanta University, Faculty of Science Department of Zoology Tanta, Egypt, Arab Republic Anterior section of palm weevil Image Stacking 4X (Objective Lens Magnification) IoD Anne Patricia Algar Hounslow, Middlesex, United Kingdom Mosquito larva Darkfield, Image Stacking, Polarized Light 4X (Objective Lens Magnification) IoD Dr. Florian Alonso University of Bordeaux BioTis-INSERM U1026 Pessac, Gironde, France Mouse aortic endothelium stained for beta-catenin (green), laminin (purple), smooth muscle actin (red), and Hoechst (cyan) Confocal 63X (Objective Lens Magnification) IoD Didier Barbet Club Français de Microscopie Bailly, France Fracture surface of mica (mineral) Differential Interference Contrast (DIC) 10X (Objective Lens Magnification) IoD Timothy Boomer WildMacro.com Vacaville, California, USA Slime mold (Prototrichia metallica) Image Stacking 10X (Objective Lens Magnification) IoD Zhang Chao National Astronomical Observatories, Chinese Academy of Sciences Beijing, China Beach sand Reflected Light 10X (Objective Lens Magnification) IoD Joshua Coogler Dallas, North Carolina, USA Moss sporophyte with spores (green) Image Stacking 10X (Objective Lens Magnification) IoD Nikky Corthout & Miranda Dyson VIB (Flanders Institute of Biotechnology) Center for Brain and Disease Research Leuven, Vlaams-Brabant, Belgium Fruit fly (Drosophila) brain vasculature Confocal, Fluorescence, Image Stacking, Super-Resolution 25X (Objective Lens Magnification) IoD Nadia Efimova Amicus Therapeutics Philadelphia, Pennsylvania, USA Dandelion pappus Confocal, Fluorescence 20X (Objective Lens Magnification) IoD Dr. Laurent Formery & Dr. Nathaniel Clarke Stanford University Department of Molecular and Cell Biology Pacific Grove, California, USA Nervous system of a young sea star Confocal, Fluorescence 10X (Objective Lens Magnification) IoD Karl Gaff Dublin, Ireland Larva of a midge fly (Chironomidae) Darkfield, Image Stacking, Polarized Light 20X (Objective Lens Magnification) IoD Dr. Nick Gatford University of Oxford Nuffield Department of Clinical Neurosciences (NDCN) Oxford, Oxfordshire, United Kingdom A network of dopaminergic neurons generated from human stem cells Super-Resolution 63X (Objective Lens Magnification) IoD Dr. Saikat Ghosh National Institutes of Health NICHD Bethesda, Maryland, USA Human neurons Confocal 40X (Objective Lens Magnification) IoD Gerd A. Günther Düsseldorf, Germany Cross section of a beach grass (Ammophila arenaria) leaf Fluorescence 20X (Objective Lens Magnification) IoD Anna-Mari Elisabeth Haapanen-Saaristo University of Turku Turku Bioscience Centre / Cell Imaging & Cytometry Core and Zebrafish Core RAISIO, Varsinais-Suomi, Finland Nutrient storage cells in a tardigrade Confocal 25X (Objective Lens Magnification) IoD Dr. Martin Hein Lions Eye Institute Physiology and Pharmacology laboratory Nedlands, Western Australia, Australia Abnormal blood vessel formation in a human retina with severe diabetic retinopathy Confocal 20X (Objective Lens Magnification) IoD Wen Jie Ji Yin Works The Bureau of Microworld Exploration Beijing, China Integrated circuit chip Reflected Light 10X (Objective Lens Magnification) IoD Ted Kinsman Rochester Institute of Technology Photosciences Department Rochester, New York, USA A common house cat claw Polarized Light 10X (Objective Lens Magnification) IoD Daniel Knop Oberzent-Airlenbach, Hessen, Germany Opening of a hibiscus flower (Hibiscus moscheutos) exposing the pollen in four stages, each ten minutes apart Image Stacking 20X (Objective Lens Magnification) IoD Daniel Knop Oberzent-Airlenbach, Hessen, Germany Dorsal part of cuckoo wasp (Hedychrum gerstaeckeri) abdomen Image Stacking 20X (Objective Lens Magnification) IoD Dr. Håkan Kvarnström Bromma, Sweden Peacock plume feather Epi-Illumination, Image Stacking 4X (Objective Lens Magnification) IoD Dr. Ewa Langner Washington University in St Louis Department of Medicine - Renal Division, Mahjoub Lab St Louis, Missouri, USA Mouse embryonic kidney showing interstitial fibroblasts (yellow), tubular epithelium (cyan), and nuclei (magenta) Confocal, Fluorescence, Image Stacking 40X (Objective Lens Magnification) IoD Dr. Amir Maqbool Lovely Professional University Department of Zoology Srinagar, Jammu and Kashmir, India Small fly killed by "zombie fly" fungus (Entomophthora muscae) Image Stacking 2X (Objective Lens Magnification) IoD Dr. Robert Markus University of Nottingham School of Life Sciences, Super Resolution Microscopy Nottingham, Nottinghamshire, United Kingdom Dandelion (Traxacum officinale) cross section showing curved stigma with pollen Confocal 10X (Objective Lens Magnification) IoD Dr. Robert Markus, Dr. Zeeshan Mohammad, Dr. Sarah Pashley & Dr. Rita Tewari University of Nottingham School of Life Sciences, Super Resolution Microscopy Nottingham, Nottinghamshire, United Kingdom Malaria parasites and mouse blood cells - tubulin (green), all proteins (purple), DNA (red) Confocal 63X (Objective Lens Magnification) IoD Jan Martinek Charles University Department of Experimental Plant Biology Prague, Czech Republic Spores of a black Bagnoli truffle (Tuber mesentericum) Confocal 63X (Objective Lens Magnification) IoD Dr. Guillermo Moya Johns Hopkins University Department of Biology Baltimore, Maryland, USA Neuronal axons connecting to the muscles of the iris and the cornea Confocal, Fluorescence 10X (Objective Lens Magnification) IoD Jacek Myslowski Wloclawek, Kujawko-Pomorskie, Poland Water mite (Arrenurus) Fluorescence, Image Stacking 6.3X (Objective Lens Magnification) IoD Aryah Nagarajan Falmouth University Institute of Photography Penryn, Cornwall, United Kingdom Spores releasing from the sori of a Polypody fern (Polypodium vulgare) Reflected Light, Transmitted Light, Focus Stacking 10X (Objective Lens Magnification) IoD Thomas Neumann Tübingen, Baden-Württemberg, Germany Ink dot on Japanese washi paper Brightfield, Image Stacking 20X (Objective Lens Magnification) IoD Satu Paavonsalo & Dr. Sinem Karaman University of Helsinki Individualized Drug Therapy Research Program, Faculty of Medicine, Helsinki, Finland Helsinki, Finland Blood vessels (color gradient) and endothelial cell nuclei (white) in the intestinal villi of a mouse Confocal 10X (Objective Lens Magnification) IoD Uwe Lange Hannover, Niedersachsen, Germany Pollen on the compound eyes of a fly Image Stacking 60X (Objective Lens Magnification) IoD Dr. Marko Pende MDI Biological Laboratory Murawala Lab Bar Harbor, Maine, USA Ladybug (Coccinellidae) on a clover (Trifolium repens) Confocal, Fluorescence, Image Stacking 4X (Objective Lens Magnification) IoD Dr. Felice Placenti FP Nature and Landscape Photography Siracusa, Sicilia, Italy Potato tuber sprout Image Stacking, Reflected Light 1X (Objective Lens Magnification) IoD Alison Pollack San Anselmo, California, USA Slime mold (Lamproderma arcyrioides) Image Stacking, Reflected Light 10X (Objective Lens Magnification) IoD Dr. Gonzalo Quiroga Artigas CRBM-CNRS Montpellier, Herault, France Tardigrade (Hypsibius exemplaris) Confocal 40X (Objective Lens Magnification) IoD Chris Romaine Kandid Kush Port Townsend, Washington, USA Bract (part of the plants reproductive structures) of a cannabis plant. The bulbous glands are trichomes. Image Stacking 20X (Objective Lens Magnification) IoD Dr. Adolfo Ruiz De Segovia PARTICULAR Madrid, Spain Plant root Fiber Optic 2X (Objective Lens Magnification) IoD Yurim Seo, Dr. Mark Looney & Dr. Simon Cleary University of California, San Francisco Pulmonary, Critical Care, Allergy and Sleep Medicine San Francisco, California, USA Lymphatic vasculature (cyan) and vessels (red) of a mouse lung Confocal 4X (Objective Lens Magnification) IoD Dr. Leo Serra University of Cambridge Sainsbury Laboratory Cambridge, Cambridgeshire, United Kingdom Leaves arising from thale cress (Arabidopsis thaliana) meristem Confocal 20X (Objective Lens Magnification) IoD Dr. Igor Robert Siwanowicz Howard Hughes Medical Institute (HHMI), Janelia Research Campus Ashburn, Virginia, USA Aster anther cross section with pollen grains (green) Confocal 40X (Objective Lens Magnification) IoD Dr. Igor Robert Siwanowicz Howard Hughes Medical Institute (HHMI), Janelia Research Campus Ashburn, Virginia, USA Floret of a common chicory with pollen grains (spiky balls) Confocal 40x (Objective Lens Magnification) IoD Luna Šošo Zdravković, Michael Surala & Christian Madry Charité Universitätsmedizin Berlin Institute of Neurophysiology Berlin, Germany Pyramidal neuron in mouse hippocampus Confocal, Fluorescence, Image Stacking 30X (Objective Lens Magnification) IoD Dr. Bruce Douglas Taubert Glendale, Arizona, USA Mid-tibial tuft on a male orchid bee, used to attract mates Reflected Light 10X (Objective Lens Magnification) IoD Maxime Teixeira Laval University Department of Molecular Medicine Québec, Canada Cultured monkey kidney cells labeled for tubulin (blue) and actin (orange) showing pathological accumulation of alpha-syn aggregates (red) Confocal, Deconvolution, Image Stacking, Super-Resolution 100X (Objective Lens Magnification) IoD Dr. Theo Theune Oost-Souburg, Zeeland, Netherlands Abdominal skin of a tick that engorged with blood Image Stacking 50X (Objective Lens Magnification) IoD Dr. Grigorii Timin & Dr. Michel Milinkovitch University of Geneva Department of Genetics and Evolution Geneva, Switzerland Skin scales of a snake embryo stained with Fast Green dye Confocal 63X (Objective Lens Magnification) IoD Steven A. Valley Oregon Department of Agriculture (ODA) Entomology Lab Albany, Oregon, USA Immature male damselfly (Calopteryx aequabilis) Image Stacking, Reflected Light 5X (Objective Lens Magnification) IoD Dr. Bruno Vellutini Max Planck Institute of Molecular Cell Biology and Genetics Dresden, Saxony, Germany Gene expression patterns in a drain fly embryo (Clogmia albipunctata) with an open eggshell Confocal 20X (Objective Lens Magnification) IoD Susannah Waxman & Dr. Ian Sigal University of Pittsburgh Department of Ophthalmology Pittsburgh, Pennsylvania, USA Optic nerve head collagen of a pig Image Stacking, Multiphoton 25X (Objective Lens Magnification) IoD Shao Yang Beijing Miteyide Culture Co., Ltd. Beijing, China Fiber of nylon stockings Polarized Light 5X (Objective Lens Magnification) IoD Chew Yen Fook Woodend, Waimakiriri, New Zealand Graffiti from Berlin Wall stone section Image Stacking, Top Illumination 10X (Objective Lens Magnification) IoD Chew Yen Fook Woodend, Waimakiriri, New Zealand Water mite (Hydrachna sp.) Darkfield, Image Stacking, Polarized Light 20X (Objective Lens Magnification) IoD Elkhan Yusifov & Dr. Martina Schaettin University of Zurich Department of Molecular Life Sciences Zurich, Switzerland Developing nervous system in the eye of a 7-day-old chick embryo Stereomicroscopy 10X (Objective Lens Magnification) IoD Ou Zhilei Guangdong Radio and Television Guangzhou, Guagndong, China Stamens of flowers (Anemone cathayensis Kitag. ex Ziman & Kadota) Image Stacking 10X (Objective Lens Magnification) About Nikon Small World Photomicrography Competition The Nikon Small World Competition is open to anyone with an interest in photography or video. Participants may upload digital images and videos directly at . For additional information, contact Nikon Small World, Nikon Instruments Inc., 1300 Walt Whitman Road, Melville, NY 11747, USA, or phone (631) 547-8569. Entry forms for Nikon's 2025 Small World and Small World in Motion Competitions are available at . About Nikon Instruments Inc. Nikon Instruments Inc. is the US microscopy arm of Nikon Healthcare, a world leader in the development and manufacturing of optical, digital imaging technology and software for biomedical applications. For more information, please visit or contact us at 1-800-52-NIKON. SOURCE Nikon Instruments Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED